Lanzhou Foci Pharmaceutical Co.Ltd(002644)
2019 Annual Report
Updated March 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Shi Aiguo, the person in charge of the company, LV Zhiying, the person in charge of accounting, and Xia Xiaoyong, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report.
All the reports of the board of directors have been considered.
This annual report involves forward-looking statements such as future plans and does not constitute the company’s substantive commitment to investors. Investors are reminded to pay attention to investment risks.
The company has pharmaceutical policy and market risks, raw material price fluctuation risks, human resource risks and operation and management risks. For details, see “IX. prospects for the future development of the company” in “section IV discussion and analysis of business conditions”. Please pay attention to the investment risks.
The company’s profit distribution plan reviewed and approved by the board of directors is: take 510657000 as the base, distribute cash dividend of 0.6 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 share (including tax), and do not use the accumulation fund to increase the share capital.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III business summary of the company Section IV discussion and analysis of business situation 15 Section V important matters Section VI changes in shares and shareholders Section VII preferred shares 49 section 8 information about convertible corporate bonds Section IX directors, supervisors, senior managers and employees Section 10 corporate governance Section 11 relevant information of corporate bonds Section XII financial report 58 section 13 list of documents for future reference one hundred and seventy-three
interpretation
Explanatory item refers to the explanatory content
Company / the company refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644)
The articles of association refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644) articles of association
Company Law refers to the company law of the people’s Republic of China and its amendments
“Securities Law” refers to the securities law of the people’s Republic of China and its amendments
Reporting period / current reporting period refers to 2019
The initial raised investment project refers to the technical transformation project to expand the production scale of concentrated pills
Lanzhou New Area Lanzhou Foci Pharmaceutical Co.Ltd(002644) science and Technology Industrial Park project, Gansu Fuci natural drug Industrial Park project, refinancing fund-raising and investment project refers to the marketing network and information construction project, and the project of Gansu Modern Traditional Chinese medicine preparation engineering technology research center
Lanzhou New Area Project / new area project refers to the project of Lanzhou New Area Lanzhou Foci Pharmaceutical Co.Ltd(002644) science and Technology Industrial Park
Fuci group refers to Lanzhou Fuci Pharmaceutical Industry Development Group Co., Ltd
Health industry company refers to Lanzhou Fuci Health Industry Co., Ltd
Chinese herbal medicine management company refers to Gansu foci Chinese Herbal Medicine Management Co., Ltd
Fat Chi Medical Company Limited
Fuci Scientific Innovation Co., Ltd. refers to Lanzhou Fuci Scientific Innovation Co., Ltd
Fuci HongRi pharmaceutical Source Co., Ltd. refers to Gansu Fuci HongRi pharmaceutical source industry sales Co., Ltd
Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) company refers to Gansu Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) Co., Ltd
Pharmaceutical industry development company refers to Gansu foci Pharmaceutical Industry Development Co., Ltd
Eco agriculture company refers to Gansu foci eco agriculture development Co., Ltd
Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) refers to Tianjin Chase Sun Pharmaceutical Co.Ltd(300026)
RMB / 10000 yuan / 100 million yuan refers to RMB / 10000 yuan / 100 million yuan
The new version of GMP refers to the good manufacturing practice (revised in 2010)
The new version of GSP refers to the code for quality management of Pharmaceutical Trading (revised in 2013)
Section II Company Profile and main financial indicators
1、 Company information
Stock abbreviation Lanzhou Foci Pharmaceutical Co.Ltd(002644) stock code Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Changed stock abbreviation (if any) none
Shenzhen Stock Exchange
Chinese name of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Chinese abbreviation of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Foreign language name of the company (if any) Lanzhou foci Pharmaceutical Co., Ltd
The abbreviation of the company’s foreign name (if any) foci pharmaceutical
The legal representative of the company is Shi Aiguo
Registered address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Postal code of registered address 730000
Office address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Postal code of office address 730000
Company website: www.fczy.com com.
E-mail [email protected].
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: LV Zhiying an Wenting
Contact address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Tel: 0931825 Hangzhou Pinming Software Co.Ltd(688109) 318362318
Fax: 09318368945
E-mail lvzhiying3619126.com. [email protected].
3、 Information disclosure and preparation location
The name of the information disclosure media selected by the company is China Securities Journal and Securities Daily
The website of the website designated by the CSRC for publishing the annual report is www.cn info. com. cn.
The company’s annual report is prepared at the office of the board of directors of the company
4、 Registration changes
Organization Code: 91620 Guangdong Golden Dragon Development Inc(000712) 762468n (Unified Social Credit Code)
Whether the changes of the company’s main business (if any) have changed since its listing
There is no change in the previous changes of controlling shareholders (if any)
5、 Other relevant information: accounting firm employed by the company
Name of accounting firm Dahua accounting firm (special general partnership)
Office address of the accounting firm: 1101, building 7, yard 16, Middle West Fourth Ring Road, Haidian District, Beijing
Signature accountant Name: Hui Quanhong, fan Cang
Recommendation agencies hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable to financial consultants hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable VI. major accounting data and financial indicators whether the company needs to retroactively adjust or restate the accounting data of previous years □ yes √ no
20192018 year-on-year increase or decrease in 2017
Operating income (yuan): 6288151640754458104624 15.47% 50113971654
Net profit attributable to shareholders of the listed company (yuan) 71107018827291822916 – 2.48% 7409278260
Deduction attributable to shareholders of listed companies non recurring
Net profit of profit and loss (yuan) -6219965394748609913 -113.10% 6397586708
Net cash flow from operating activities (yuan) 47822985373666311205 30.44% 6642306238
Basic earnings per share (yuan / share) 0.1392 0.1428 – 2.52% 0.1451
Diluted earnings per share (yuan / share) 0.1392 0.1428 – 2.52% 0.1451
Weighted average return on net assets 4.83% – 5.21% – 0.38% – 5.58%
At the end of 2019, at the end of 2018, there is an increase or decrease in the end of 2017 compared with the end of the previous year
Total assets (yuan) 240068696623252400117854 – 4.89% 234982516017
Net assets attributable to shareholders of the listed company (yuan) 150691150621144042789080 4.62% 135914820264
7、 Differences in accounting data under domestic and foreign accounting standards 1. Differences in net profit and net assets in financial reports disclosed in accordance with international accounting standards and Chinese accounting standards □ applicable √ not applicable
During the reporting period, there is no difference in net profit and net assets in the financial reports disclosed in accordance with international accounting standards and Chinese accounting standards.
2. At the same time, the difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards □ applicable √ not applicable. The company has no net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards in the reporting period
